371 related articles for article (PubMed ID: 25523385)
1. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
Cardoso SW; Luz PM; Velasque L; Torres TS; Tavares IC; Ribeiro SR; Moreira RI; Veloso VG; Moore RD; Grinsztejn B
BMC Infect Dis; 2014 Dec; 14():699. PubMed ID: 25523385
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.
Napravnik S; Eron JJ; Sterling TR; Juday T; Uy J; Moore RD
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):574-80. PubMed ID: 23072322
[TBL] [Abstract][Full Text] [Related]
3. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
[TBL] [Abstract][Full Text] [Related]
4. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.
Martin DA; Luz PM; Lake JE; Clark JL; Veloso VG; Moreira RI; Cardoso SW; Klausner JD; Grinsztejn B
BMC Infect Dis; 2014 Jun; 14():322. PubMed ID: 24919778
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of second-line antiretroviral therapy: the impact of drug switches.
Braga LP; Mendicino CCP; Reis EA; Carmo RA; Menezes de Pádua CA
AIDS Care; 2017 Dec; 29(12):1585-1588. PubMed ID: 28490196
[TBL] [Abstract][Full Text] [Related]
6. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
[TBL] [Abstract][Full Text] [Related]
7. Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil.
Calvet GA; Velasque L; Luz PM; Cardoso SW; Derrico M; Moreira RI; de Andrade AC; Cytryn A; Pires E; Veloso VG; Grinsztejn B; Friedman RK
PLoS One; 2014; 9(2):e89299. PubMed ID: 24586673
[TBL] [Abstract][Full Text] [Related]
8. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
9. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011.
Sheth AN; Ofotokun I; Buchacz K; Armon C; Chmiel JS; Hart RL; Baker R; Brooks JT; Palella FJ
J Acquir Immune Defic Syndr; 2016 Jan; 71(1):47-56. PubMed ID: 26334737
[TBL] [Abstract][Full Text] [Related]
11. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
[TBL] [Abstract][Full Text] [Related]
12. Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) and Early-treated Perinatally HIV-infected Individuals: Improving Childrenʼs Actual Life with Novel Immunotherapeutic Strategies (EPIICAL) study groups
AIDS; 2019 Jun; 33(7):1155-1165. PubMed ID: 30741823
[TBL] [Abstract][Full Text] [Related]
13. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
14. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy.
Wamalwa DC; Lehman DA; Benki-Nugent S; Gasper MA; Gichohi R; Maleche-Obimbo E; Farquhar C; John-Stewart GC; Overbaugh J
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):267-74. PubMed ID: 23196827
[TBL] [Abstract][Full Text] [Related]
15. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
16. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
[TBL] [Abstract][Full Text] [Related]
17. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.
Fairlie L; Karalius B; Patel K; van Dyke RB; Hazra R; Hernán MA; Siberry GK; Seage GR; Agwu A; Wiznia A;
AIDS; 2015 Oct; 29(16):2109-19. PubMed ID: 26182197
[TBL] [Abstract][Full Text] [Related]
18. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil.
Cardoso SW; Grinsztejn B; Velasque L; Veloso VG; Luz PM; Friedman RK; Morgado M; Ribeiro SR; Moreira RI; Keruly J; Moore RD
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):865-74. PubMed ID: 20672997
[TBL] [Abstract][Full Text] [Related]
19. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
20. Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy.
Szadkowski L; Tseng A; Walmsley SL; Salit I; Raboud JM
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1579-83. PubMed ID: 22734840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
